Running title: A PML-I/thrombospondin-2 axis regulates angiogenesis and neuroblastoma relapse. Dvorkina et al. A promyelocytic leukaemia protein-thrombospondin 2 axis and the risk of relapse in neuroblastoma 3 Abstract Purpose. Neuroblastoma is a childhood malignancy originating from the sympathetic nervous system with a complex biology, prone to metastasize and relapse. High-risk, metastatic cases are explained in part by amplification or mutation of oncogenes such as MYCN and ALK and loss of tumour suppressor genes in chromosome band 1p. However, it is fundamental to identify other pathways responsible for the large portion of neuroblastomas with no obvious molecular alterations.
Introduction
The Promyelocytic Leukaemia protein (PML) is a growth/tumour suppressor inactivated in Acute
Promyelocytic Leukaemia (APL) via the t(15;17) translocation. PML is expressed as multiple splice variants and is the essential component of a subnuclear structure called the PML nuclear body (PML-NB), which is disrupted in APL (1) . PML has emerged as pleiotropic growth suppressor affecting multiple cellular pathways involved in tumourigenesis, in part via recruitment of nuclear factors to the PML-NBs, also required for activation of p53 (2) (3) (4) (5) (6) (7) (8) . One of the main physiological roles of PML is its ability to regulate cell fate in stem/progenitor cells in multiple tissues (9) . In the nervous system, we have shown that PML regulates neurogenesis and cortex development by modifying the Retinoblastoma (pRb) G1/S checkpoint (9, 10) . Most growth and tumour suppressive activities of PML have been linked to the splice variant PML-IV (11), whereas little is known about the other more abundant variants, such as PML-I (12, 13) .
PML expression is lost in tumours of multiple histological origins, and its inactivation has been shown to promote tumour progression in APL, prostate and lung cancer (5, (14) (15) (16) . In contrast, it may play an oncogenic role in chronic myeloid leukaemia and breast cancer (17, 18) . PML role in tumours of the nervous system has not been investigated.
Neuroblastoma is the most common extra-cranial solid tumour in childhood and the most frequently diagnosed malignancy in infancy. It accounts for 8% of cancer cases in children and approximately 15% of all childhood cancer deaths, highlighting the aggressive nature of this tumour (19, 20) . The tumour develops from neural crest-derived sympathoadrenal precursor cells (20) . Neuroblastoma is characterized by a number of genetic aberrations; these include ploidy changes, gains of chromosome arm 17q, amplification of the proto-oncogene MYCN, activating mutations of ALK, and deletions of different genomic regions containing putative Dvorkina et al. A promyelocytic leukaemia protein-thrombospondin 2 axis and the risk of relapse in neuroblastoma 5 tumour suppressor genes in chromosome bands 11q23, 1p36 and 14q23-qter (19, (21) (22) (23) (24) .
Neuroblastomas commonly arise from the medullary region of the adrenal gland (20, 25) and are classified into five stages (1-4 and 4S), according to the International Neuroblastoma Staging System (INSS) (26, 27) . Low-risk patients (stages 1, 2 and 4S with a favourable histology) have a survival rate greater than 85% whereas the survival rate for high-risk neuroblastoma (stages 3,4 with unfavourable histology and MYCN amplification) is less than 50% in spite of multimodal therapy, reflecting the propensity of the tumour to relapse into a treatment resistant, fatal form of the disease (20, 27, 28) . Recurrent neuroblastoma in patients initially classified as low-risk is uncommon, but can develop into an intractable cancer. It would be very important to identify patients at risk of recurrence needing chemotherapy in addition to surgical removal of the localized tumour mass.
In this study, we show that PML expression inversely correlates with tumour relapse in localized neuroblastomas and is lost in aggressive forms of human and mouse neuroblastomas. The PML-I isoform, when overexpressed in neuroblastoma cells, does not affect proliferation or survival, but instead it suppresses angiogenesis in vitro and in vivo. Mechanistically, PML-I inhibits angiogenesis by upregulating Thrombospondin-2, a known angiogenesis suppressor.
Finally, PML-I expression inversely correlates with tumour angiogenesis in primary tumour samples. Overall, these data implicate PML in isoform-specific regulation of neuroblastoma pathogenesis and suggest that it may serve as predictor of relapse in localized neuroblastoma.
Materials and Methods
Cell culture. IMR32, SH-EP, SK-N-SH, SK-N-AS, Kelly, NB69 and LAN-5 human neuroblastoma lines were a kind gift from Dr Louis Chesler's lab (Institute of Cancer Research, London, UK). SHSY5Y human neuroblastoma cell line was purchased from ATCC. The cells were cultured in DMEM-or RPMI-based media supplemented with 10% foetal calf serum, 2 mM L-glutamine, 100 mg/mL penicillin and 100 mg/mL streptomycin.
For ex vivo mouse neural crest trunk progenitor cultures, the neural tubes were dissected from e9.5 C57BL/6 mouse embryos, and the trunk section of the tube was placed on laminin/fibronectin-covered coverslip and left to attach in a drop of dissection medium (DMEM:F-12 medium 1:1 +5%FCS+100 mg/mL penicillin+100 mg/mL streptomycin). The explants were cultured for 24-48 hours in neural tube culture medium (DMEM/F12 1:1 supplemented with N2, B27 (both Invitrogen), bFGF 20ng/ml and EGF 20ng/ml. The coverslips with the neural tube explants and migrated progenitors were fixed in 4% PFA and used for immunostaining.
Cell proliferation assessment. Cells were plated in 12-well plates and cultured until fully confluent. During the culturing period, images were acquired at regular intervals using IncuCyte live-cell imaging system (Essen Biosciences) and processed using the IncuCyte software to calculate the growth rates.
Patients and Clinical Follow-up.
A retrospective series of primary tumours from neuroblastoma (NB) patients (Table 1, Supplementary Tables 1 and 2 were selected subjectively from each tumour section. The micro-vessels with a clearly defined lumen or well-defined linear vessel shape were taken into account for MVC.
Digital images were collected using a Nikon E-1000 fluorescence microscope (Nikon Instruments, Tokyo, Japan) equipped with appropriate filter sets and the Genikon imaging system software (Nikon Instruments). 
Constructs, transfection, retroviral/lentiviral infections. Human PML-I isoform and PML-IV
isoform coding sequences were cloned into the pBabe puro and pBabe hygro retroviral vectors, respectively (9) . shPML pLKO and pLKO scrambled lentiviral plasmids were a kind gift from the Everett's lab (32) . pGIPZ eGFP PML, TSP2 and pGIPZ eGFP scrambled plasmids were purchased from Open Biosystems/Dharmacon and lentiviral supernatants were prepared according to the manufacturer's protocol (most efficient sequences were used for the study).
The sequence of the shRNA (GIPZ Clone V3LHS_402844) used for TSP2 downregulation studies was TATATGTAAACGTCATTCT. After infection the cells were cultured in presence of puromycin or hygromycin to select for infected cells. Microarray. Total RNA was extracted from IMR32 pBpuro and PML-I-OE using Qiagen RNeasy
Mini Kit 74104 (n=2). cDNAs labelled were prepared with SuperScript III RT kit (Invitrogen) using 5 µl of total RNA. Microarray slides were pre-hybridized in 3X SSC, 0.1% (w/v) SDS and 10 mg/ml bovine serum albumin (BSA) at 60 0 C for 20 min. Following pre-hybridization, slides
were washed with distilled water for 1 minute and isopropanol for 1 minute, dried with an airbrush and pre-scanned to check for any array defects.
The capture sequence-tagged cDNAs were hybridized onto the microarray slide for 16 h at 55 0 C in a SlideBooster SB400 (Advalytix) with the power setting at 27 and a pulse:pause ratio of 3:7. The slides were washed in 2xSSC, 0.2% (w/v) SDS for 10 min at 55 0 C and then for 10 min at room temperature. The slides were dried and hybridized with the Cy3 and Cy5 dendrimers (3DNA 900, Genisphere) following manufacturer's instructions. Dried slides were scanned using a Inno Scan 700 (Innopsys) using autocalibration to obtain optimized non-saturating images for each fluorophore and analysed using BlueFuse for Microarrays (BlueGnome).
The data underwent Cross Channel Correction, followed by Lowess Normalisation. After normalising the data, the mean fold ratio value was derived and a cyber-T test was performed to generate a p-value. The software BASE was used to carry out the normalization. Table   2 ). constructed by using the Kaplan-Meier method.
Results
We have previously shown that PML is expressed in neural progenitor/stem cells of the developing neocortex (9) . In order to evaluate its expression during development of the peripheral nervous system, we performed immunohistochemical analysis of neural crest progenitors of the sympathetic nervous system and, postnatally, in the adrenal gland medulla.
PML was found expressed in a subset of embryonic p75-positive progenitors delaminating from the neural tube and in TH-positive cells in the developing and adult adrenal medulla ( Figure 1A) .
Similarly, in vitro cultures of neural tube-derived progenitors showed PML accumulating in a subset of p75-and Sox10-positive cells ( Figure 1B ).
As neuroblastoma is believed to originate from progenitor cells of the developing sympathetic nervous system (20), we evaluated PML expression in neuroblastomas arising in tyrosinehydroxylase (TH)-MYCN-transgenic mice, and found that it was downregulated in most tumours analysed ( Figure 1C ), whereas it was expressed in the normal adrenal gland (N). We next assessed the expression of PML in primary neuroblastoma patients at presentation by immunohistochemical or immunofluorescence analysis in two independent cohorts. We showed that PML expression is high in the adult human adrenal medulla, but it is generally low in neuroblastomas ( Figure 1D ; tumours shown are part of Cohort 2 listed in Supplementary Table   1) . Notably, the cumulative survival probability of patients whose localised tumours contained more than 40% of PML positive cells was excellent, with 100% event free survival probability after 7 years from diagnosis ( Figure 1E ; tumours shown are part of the Cohort 1 listed in Supplementary Table 1) . In stark contrast, survival probability of patients whose tumours contained less than 40% PML positive cells was only 10% after 2 years ( Figure 1E ). There was a striking correlation between low expression (<40% positive cells) of PML and tumour recurrence in localised, low-risk, patients, suggesting that PML expression may represent an accurate biomarker of relapse ( Figure 1E , Supplementary Table 2 and Supplementary Figure 1A) . PML expression in MYCN-non-amplified tumours (all stages) and MYCN-non-amplified stage 4 tumours was significantly associated with a reduced risk of tumour relapse (Supplementary   Table 2 and Supplementary Figure 1B , C).
We next investigated PML expression in a panel of neuroblastoma cell lines. As mentioned above, there are several splice variants that produce seven or more protein isoforms, which retain a common tripartite motif but vary in their C-termini (12, 34) . Analysis of total PML expression by Western Blotting and immunofluorescence analyses (Figure 2A , B) using a pan-PML antibody showed that a number of cell lines display low PML expression, with the most prominent PML isoform migrating at around 90-100 kilodalton (kDa), which corresponds to the PML-I (and PML-II) isoforms (Figure 2A) . The mRNA levels of PML-I generally correlate with the high-molecular weight PML isoform ( Figure 2C ). These findings suggest that there is, at least in part, a selective expression of PML isoforms in neuroblastoma cell lines. We then assessed the Figure 3A, B) . Indeed, immunofluorescence analysis of the CD31 endothelial marker, revealed that there was a significant reduction in vascular clusters in PML-I compared to control tumours ( Figure 3C ).
Furthermore, decreased angiogenesis in PML-I tumours correlated with enrichment in S100-positive Schwann-like cells, typically associated with low-risk forms of neuroblastoma (26, 27) , and reduced number of cells expressing the neuroblast marker CD56 ( Figure 3D ). This effect did not appear related to a cell-autonomous effect of PML-I on S100, as expression of this marker was not increased in PML-I-overexpressing cells in vitro (not shown).
These results prompted us to investigate whether PML-I-expressing cells secrete antiangiogenic factor(s) that could explain the observed phenotype. We used supernatants from PML-I or empty vector-infected IMR32 cells in endothelial cell tubule formation assays with human umbilical vascular endothelial chord (HUVEC) cells. We observed inhibition of tubule number, length and branching when HUVEC cells were exposed to the PML-I, but not control, supernatants ( Figure 3E ). These in vitro results were corroborated by immunofluorescence analysis in neuroblastoma patients that confirmed that there was a statistically significant inverse correlation between CD31 positive microvessel clusters and PML expression ( Figure   3F , G and Table 1 ). Thus, PML regulates angiogenesis in vitro and in vivo.
We next studied the potential mechanisms involved. Based on previous studies (35) , the PML-IV isoform controls angiogenesis via an mTOR/HIF1α/vascular endothelial growth factor (VEGF) axis in fibroblasts and prostate cancer. However, we failed to detect differences in HIF1α levels in either normoxic or hypoxic conditions ( Supplementary Figure 2A) , thus implicating different mechanisms underlying PML-I-mediated regulation of angiogenesis in neuroblastoma.
Therefore, we set out to study the potential effect of PML-I on gene expression. We analysed gene expression in PML-I and pBabe control IMR32 cells using custom-made arrays. As Figure 2C) . Finally, by using PML-I-and TSP-2-specific antibodies tissue sections from neuroblastoma patients were scored as the percentage of stained nuclear and cytoplasm respectively neuroblastoma cells ( Figure 4E ). We revealed a correlation between expression of PML-I and TSP-2 (Spearman's correlation rank r=0.89),
suggesting that the functional relationship is conserved in primary neuroblastoma (Table 2) .
Overall, our findings indicate that the tumour suppressor PML suppresses angiogenesis at multiple levels via the specialised functions of two of its splice forms, PML-I and PML-IV.
Discussion
Localised tumours without amplification of MYCN is a group of particular interest due to a difficult risk estimation resulting in quite different therapeutic options (intermediate-risk chemotherapy versus wait-and-see strategy without chemotherapy) (39, 40) . In this study, we have established that loss of PML expression identifies patients with localised disease at risk of tumour relapse that will potentially benefit from chemotherapeutic treatment, suggesting that PML could be used as a marker to guide therapeutic intervention. Interestingly, PML did not appear to act as a growth suppressor in neuroblastoma, as transduction of the growth suppressive PML-IV isoform in PML low neuroblastoma cells only marginally inhibited cell growth, whereas PML-I had no effect on either cell or tumour growth. In contrast, transduction of PML-I led to inhibition of angiogenesis both in vitro and in vivo. We cannot exclude that prolonged observation of tumour growth could have revealed differences in tumour size as well, but we could not extend the analysis due to animal welfare regulations. These data indicate an isoformspecific PML role in regulation of angiogenesis in neuroblastoma. Notably, PML expression inversely correlated with tumour angiogenesis index in patient samples. More generally, these findings suggest a novel role for tumour angiogenesis in relapse of localized tumours.
It is interesting to note that PML-IV was reported to inhibit angiogenesis via an mTOR/HIF1α-dependent mechanism (35), but we failed to detect an angiogenesis role of PML-IV in neuroblastoma nor changes in HIF1α protein levels. Instead, PML-I appears to work as a HIF1α− angiogenesis suppressor via transcriptional regulation of thrombospondin-2 (TSP2), a known inhibitor of angiogenesis and tumourigenesis (36, 37, 41) .
Although it remains to be determined how PML-I could regulate TSP2, our findings suggest that a novel PML-I/TSP2 signalling module suppresses tumour angiogenesis in neuroblastoma.
Considering the effect of PML-I expression on the retinoblastoma pathway (see Pathway Analysis and (9)), one could speculate that pRb/E2Fs regulates TSP2 gene expression. In this respect, as oncogenic RAS is known to inhibit the expression of TSP2 in tumour cells (42), it could be hypothesized that TSP2 induction could be part of a PML/pRb tumour suppressive checkpoint triggered by RAS activation in normal cells (43) .
Another finding of our study is the association between reduced angiogenesis and increased expression of Schwann-like markers in PML-I-overexpressing tumours. The presence of Schwann-like differentiation in neuroblastoma is a good prognostic marker and has been found associated with reduced angiogenesis (44) , although it is still debated whether cells carrying Schwann markers with neuroblastoma tumours are of tumour origin (45, 46) . A previous report suggested that PML expression correlates with the Schwann-like phenotype in cell lines and that reintroduction of PML in PML low Neuronal (N-type) cells induced neurite extension (47) .
However, we failed to observe a differentiation-promoting effect of PML in N-type IMR32 cells nor increased expression of the Schwannian marker S100 in vitro. Thus, our study suggests that PML may regulate Schwannian differentiation within neuroblastoma tumours via angiogenesis inhibition or that TSP2 itself may have direct pro-differentiation properties in vivo.
In keeping with this, TSP2 has been shown to induce synaptogenesis in the central nervous system (48) and chondrogenic differentiation in the bone (49).
In conclusion, our study reveals a novel PML-I/TSP2 axis regulating neuroblastoma angiogenesis and differentiation, which could serve as biomarker to predict relapse in localized neuroblastoma. More generally, PML is emerging as key player in angiogenesis regulation via the ability of two of its splice forms, PML-I (the present study) and PML-IV (35) to control different steps of the angiogenesis process. 
